ClinicalTrials.gg
CompletedNCT06787170PPRPHGSOCUpdated Jan 23, 2025

Prediction of Platinum Resistance and Prognosis of High-grade Serous Ovarian Cancer

An observational study in High-grade Serous Ovarian Cancer (HGSOC), sponsored by The First People's Hospital of Yunnan. Completed at 1 site in China. Open to female participants. Per ClinicalTrials.gov, last updated 2025-01-23.

Sponsored by The First People's Hospital of Yunnan · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Retrospective
Enrollment
1,129
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 395 studies in Ovarian Neoplasms with a site in China — 201 open to participants now, 233 under way, 36 of them phase 3. Ovarian Neoplasms · China.

Enrollment
15th of 73
1,129 · median 200
Started
2022
with 46 others
Observational
73 of 395
36 open now
Registered
300th of 395
by date

Among the 395 studies in Ovarian Neoplasms with a site in China, this one is the 15th largest by enrollment of the 73 observational ones that give a count, is one of 47 that started in 2022, is one of 73 observational ones, and was the 300th registered.

Ovarian Neoplasms

3,390 studies on the registry are indexed under Ovarian Neoplasms; 790 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

201 of the 395 studies in Ovarian Neoplasms with a site in China are open now. Recruiting first, the newest first:

196 more — sign in →

All 201 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 603 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.

This study: female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 395 studies in Ovarian Neoplasms with a site in China, or all of them as a file.
02

Study summary

High-grade serous ovarian carcinoma (HGSOC) is the most common subtype of ovarian carcinoma. Platinum-based drugs are the first-line chemotherapeutic agents for HGSOC, but platinum resistance and prognosis are difficult to predict. Domestic and foreign studies have found that multi-functional MRI could reflect the macroscopic heterogeneity of tumors from different perspectives; habitat imaging contributed to reflecting the spatial heterogeneity of tumors; the attention mechanism could integrate features of different scales; and multi-omics were capable to improve predictive performance. Previously, our team has demonstrated the importance of MRI and its functional imaging in the diagnosis and histological evaluation of gynecological tumors. And conventional MRI habitat imaging, multi-instance learning based on whole slide image (WSI), and multi-omics model could effectively predict platinum resistance in HGSOC patients. Therefore, this study aims to perform habitat imaging on multi-functional MRI such as multi b-value DWI and DCE-MRI and to train WSI-based multi-instance learning to construct pathological signature. Then, combined with clinical indicators, radiomics based on MRI habitat, and pathomics, a multi-omics fusion model trained by attention mechanism was constructed. Finally, to explore the value of MRI habitat, WSI, and multi-omics in predicting platinum resistance and prognosis in HGSOC patients. This study combines macroscopic functional imaging and microscopic pathological information to construct a multi-omics complementary model, which can predict platinum resistance and prognosis of HGSOC patients more comprehensively and accurately, and further guide the formulation of clinical treatment.

03

Conditions studied

  • High-grade Serous Ovarian Cancer (HGSOC)

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

HGSOC patients confirmed by surgery and pathology

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients diagnosed as HGSOC based on surgery and pathology.
  • The standard treatment including surgical cytoreduction followed by at least three cycles of regular platinum-based chemotherapy after surgery.
  • Follow-up records available for more than six months after postoperative chemotherapy.
  • For MRI analysis, pelvic MRI examination including axial T2-weighted imaging (T2WI), contrast-enhanced T1-weighted imaging (CE-T1WI), and diffusion-weighted imaging (DWI) was performed within two weeks prior to treatment, and patients had no any treatments other than chemotherapy (NACT) performed between MRI and surgery.

Exclusion criteria

Exclusion Criteria:

  • Patients with a history of platinum-based chemotherapy for other .
  • Absence of essential clinical data.
  • For MRI analysis, patients with poor MRI imaging quality and registration, or a tumor maximum diameter \< 1 cm on MRI needed to be excluded.
  • For pathology analysis, patients without H\&E-stained WSIs or with poor WSI imaging quality should be excluded.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Other
Time perspective
Retrospective
Enrollment
1,129 participants (actual)
Patient registry
No

Interventions

  • Diagnostic testMRI habitat imaging

    Habitat imaging, a data-driven image processing technique that divides the entire lesion into multiple sub-regions without assuming anything prior, has capacity to noninvasively evaluate the intratumoral heterogeneity.

    Also known as: radiopathomics

06

What researchers measure

Primary outcomes

  1. platinum resistance

    Platinum resistance is determined based on whether there is disease progression during or within 6 months after termination of platinum-based chemotherapy.

    Time frame: within 6 months

07

Study locations

1 site
  • the First People's Hospital of Yunnan Province
    Kunming, Yunnan 400016, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2022 to primary completion in Dec 2023, 13 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2025
First posted
Jan 22, 2025
StartActual
Nov 1, 2022
Primary completionActual
Dec 1, 2023
CompletionActual
May 31, 2024
Last update
Jan 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06787170
Lead sponsor
The First People's Hospital of Yunnan
Responsible party
Qiu Bi (Dr., The First People's Hospital of Yunnan) — Principal investigator
First posted
Jan 22, 2025
Start date
Nov 1, 2022
Primary completion
Dec 1, 2023
Completion
May 31, 2024
Last update
Jan 23, 2025

Study contacts

Qiu Bi
principal investigator · The First People's Hospital of Yunnan

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion